（编辑 任世碧） 证券日报网讯 1月12日，中盐化工在互动平台回答投资者提问时表示，公司持续聚焦主业，推进优势板 块规模化、高端化、差异化，提升优势产品的产业引领力、标准影响力、价格主导力和价值创造力；推 动传统产业优化升级，绿色化数字化智能化发展；积极布局新业务领域，拓展新发展空间，塑造新的竞 争优势，推动企业高质量发展。 ...

Investment Rating - The report assigns an "Accumulate" rating for the company for the first time [2]. Core Insights - The company, as the first publicly listed mineral water company in China, is expected to benefit from national expansion, which will provide significant growth opportunities [6][68]. - The company has a strong strategic focus on its core business of natural mineral water, with plans to reduce losses in non-core segments [27][28]. - The mineral water industry is projected to grow steadily, with the company positioned to capture market share due to its unique water source and regional brand strength [60][66]. Financial Performance Summary - Revenue projections for the company are as follows: 2023A at 1,122 million CNY, 2024A at 1,198 million CNY, 2025E at 1,274 million CNY, 2026E at 1,450 million CNY, and 2027E at 1,722 million CNY, with growth rates of -12%, 7%, 6%, 14%, and 19% respectively [2]. - The net profit forecast shows a significant turnaround from a loss of 457 million CNY in 2023A to a profit of 30 million CNY by 2027E, with growth rates of -900%, 101%, 137%, 40%, and 47% respectively [2]. - Earnings per share (EPS) are expected to improve from -0.64 CNY in 2023A to 0.04 CNY in 2027E [2]. Market Position and Competitive Landscape - The company holds a 5% market share in the national mineral water market, with a strong presence in the Northeast region, where it has a reputation for high-quality water [6][69]. - The mineral water market in China is characterized by high concentration, with the leading brand holding an 80% market share, while the company is the only one among the top five brands to achieve sales growth in the past year [60][63]. - The overall packaging water market is expected to reach 224.23 billion CNY in 2025, with a growth rate of 3% [54]. Strategic Initiatives - The company is focusing on expanding its production capacity, with plans to increase output by 400,000 tons from its core water source and an additional 2 million tons from a secondary strategic source, potentially leading to a revenue increase of 2.633 billion CNY [6][68]. - A new logistics model combining rail, sea, and road transport is set to enhance cost efficiency and improve profit margins [6][28]. - The company is actively pursuing partnerships and collaborations to enhance its market reach, including significant contracts with major airlines and retail platforms [6][68].

Core Viewpoint - Yunnan Tourism is focusing on its core business and aims to enhance sustainable operations and improve efficiency through increased R&D efforts, product and business model innovation, and lean management practices [2] Group 1 - The company is committed to sustainable operations in its existing business [2] - Yunnan Tourism plans to enhance efficiency through various initiatives [2] - The focus will be on innovation in products and business models [2]

Core Viewpoint - Yunnan Metallurgical Group is attempting to divest its 3.18% stake in Chengtai Insurance for a base price of 184 million yuan, marking the third attempt to sell this stake amid a cooling insurance equity market [2][3][4]. Group 1: Divestment Attempts - The stake has been listed for sale three times, with previous attempts in November 2023 and October 2024, where the base price dropped from 156 million yuan to 125 million yuan, both ending in failure [2][3]. - The current listing price of 184 million yuan is an increase from previous attempts, indicating a strategic shift in Yunnan Metallurgical's approach to divestment [2][3][4]. Group 2: Market Context - The insurance equity market has been generally sluggish, with many insurance companies struggling to attract investors for their equity offerings [4][5]. - The increase in listing price may reflect Yunnan Metallurgical's strategy to establish a higher value baseline and attract serious strategic investors rather than making a hasty sale [5][6]. Group 3: Regulatory Environment - The divestment aligns with the broader trend among state-owned enterprises to return to core business operations and divest non-core financial assets, as emphasized by recent government directives [3][4]. - The "退金令" (Return of Capital Order) from the State-owned Assets Supervision and Administration Commission mandates state-owned enterprises to focus on their primary business and restrict new investments in financial institutions [3][4]. Group 4: Chengtai Insurance's Financial Health - Chengtai Insurance, established in 2011, has a registered capital of 5.97 billion yuan and is the only national property insurance company headquartered in Yunnan [7][9]. - The company has faced significant financial challenges, reporting a net loss of 250 million yuan in 2023 and further losses in 2024, with a combined cost ratio exceeding 109.78% [9][10]. - However, there are signs of recovery in 2025, with a reported net profit of 19 million yuan in the first three quarters and a projected revenue of 1.997 billion yuan by November 2025 [10][20]. Group 5: Governance and Ownership Issues - A significant portion of Chengtai Insurance's shares, approximately 56.96%, are under pledge or freeze, which poses risks to corporate governance and decision-making efficiency [7][8][9]. - The high level of pledged shares indicates financial strain among shareholders, complicating the company's ability to raise additional capital for growth [19][20]. Group 6: Market Valuation Trends - The valuation of insurance equity is shifting from a focus on "license premiums" to a more rigorous assessment of profitability and capital efficiency, reflecting a broader market recalibration [21]. - The liquidity of insurance equity assets has decreased, indicating a re-evaluation of investment value in the insurance sector, which may lead to a concentration of capital in leading firms while smaller companies face long-term valuation pressures [21].

Core Viewpoint - The company will continue to focus on its main business and leverage the advantages of state-owned capital to strengthen its market presence and expand into OTC and untapped areas [1] Group 1: Business Strategy - The company is concentrating on two exclusive core products: Yuanhu Zhitong Pill and Xuanfei Zhiso Mixture, aiming to consolidate its existing market [1] - The company plans to actively expand into the generic drug market, health products line, and medical devices to cultivate new growth points [1] Group 2: Research and Development - The company is committed to increasing R&D investment and enhancing its R&D capabilities, aiming to build a collaborative innovation system and a long-term mechanism for R&D investment [1] - The company will continue to promote the secondary development of its main products while increasing R&D efforts in new drugs, classic formulas, and health-related fields to enrich its product pipeline and enhance core competitiveness [1]

Core Viewpoint - The company, Shengxing Group Co., Ltd., has decided to withdraw from participating in the establishment of Haixia Life Insurance Co., Ltd., citing changes in the investment environment and a focus on its core business development [1][4]. Group 1: Announcement Details - On December 31, 2025, the company held its 18th meeting of the fifth board of directors, where the proposal to withdraw from the establishment of the insurance company was approved with 7 votes in favor, 0 against, and 0 abstentions [1][4]. - The company will not invest in Haixia Life Insurance and has not made any actual contributions to it as of the announcement date [1][5]. Group 2: Reasons for Withdrawal - The company noted that Haixia Life has been in the approval process since August 2016 and has not yet received approval from the National Financial Regulatory Administration [1][5]. - The initial conditions for the investment assessment have changed significantly, prompting the company to reconsider its involvement in light of recent macroeconomic and financial policy changes [1][5]. - The decision aims to optimize resource allocation and focus on the company's main business development [1][5]. Group 3: Company Background - Shengxing Group was established in 1992 and is headquartered in Fuzhou Economic and Technological Development Zone, specializing in the food and beverage industry [2]. - The company operates as a multifunctional, composite group listed enterprise, involved in metal packaging production, beverage filling, marketing services, equipment R&D, supply chain services, and industrial services [2].

Core Viewpoint - The company, Shengxing Co., Ltd. (002752.SZ), has decided to withdraw from participating in the establishment of Haixia Life Insurance due to significant changes in the foundational conditions for investment evaluation and the macroeconomic environment since the initial proposal in August 2016 [1] Group 1 - Haixia Life Insurance has not yet obtained approval from the National Financial Regulatory Administration since its application process began in August 2016 [1] - The company has conducted a thorough review and determined that focusing on its main business and optimizing resource allocation is more beneficial [1] - The decision reflects the company's response to changes in the financial policy landscape and the actual circumstances surrounding the investment project [1]

Core Viewpoint - The company, Angli Education (600661.SH), is selling a 0.3034% stake in its associate company, Shenwan Hongyuan Futures Co., Ltd., to focus on its core business and optimize asset structure and resource allocation [1] Group 1: Transaction Details - The stake is being sold for 14.35 million yuan, which represents a 7.05% premium over the book value of 13.4045 million yuan [1] - The controlling shareholder of Shenwan Futures, Shenwan Hongyuan Securities Co., Ltd., has the right of first refusal for this stake [1] - The sale is expected to increase Angli Education's net assets by approximately 950,000 yuan, with the final amount subject to the annual audit report by the accounting firm [1]

Group 1 - The core point of the article is that Bluestar Medical (002382) plans to sell its wholly-owned subsidiary, Wuhan Bikaier Rescue Supplies Co., Ltd., to focus on its core business and enhance cash reserves [1] - The transaction is expected to involve cash consideration and aims to activate existing assets while shortening management radius [1] - The buyer of the subsidiary is Wuhan Mingde Biological Technology Co., Ltd. (002932.SZ), which is a listed company on the Shenzhen Stock Exchange and is not considered a related party to Bluestar Medical [1]

Core Viewpoint - The company, Angli Education (600661.SH), plans to sell its 0.3034% stake in Shenwan Futures to optimize its asset structure and improve operational efficiency [1] Group 1: Company Actions - Angli Education holds a 0.3034% equity stake in Shenwan Futures, which is a subsidiary of the company [1] - The company intends to sell this stake to focus on its main business and enhance resource allocation [1] - The stake will be sold for 14.35 million yuan to Shenwan Hongyuan, the controlling shareholder of Shenwan Futures, following mutual agreement [1]